HUTCHMED (Stock Code: 00013) announced that 19,913 ordinary shares previously granted to Executive Director, Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su under the company’s Long-Term Incentive Plan (LTIP) on 13 March 2024 fully vested on 13 March 2026.

The shares, carrying a par value of US$0.10 each and identified under ISIN KYG4672N1016, were awarded on a non-performance basis and vested at no consideration. The transaction was disclosed in line with the UK Market Abuse Regulation and Hong Kong Listing Rule 13.10B.

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. The company has three marketed medicines in China, with its lead product also approved in the US, Europe and Japan.